Business
/C O R R E C T I O N -- Pillar Biosciences, Inc./
Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based kitted liquid biopsy tumor profiling to include China.
About this update from Astrazeneca Plc
[{"type":"text","content":"In the news release, Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China, issued 08-Dec-2025 by Pillar Biosciences, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:","length":306,"tagName":"p"},{"type":"heading","content":"Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China","length":83,"tagName":"h3","attribs":{}},{"type":"text","content":"NATICK, Mass., Dec. 8, 2025 /PRNewswire/ -- Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based kitted liquid biopsy tumor profiling to include China.","length":219,"tagName":"p"},{"type":"image","alt":"Dan Harma, Chief Commercial Officer, Pillar Biosciences (PRNewsfoto/Pillar Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Dan Harma, Chief Commercial Officer, Pillar Biosciences (PRNewsfoto/Pillar Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/2498c6bdcfa654a6f660c10cf6ae4c47"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C4T9mzMZTuU3upY7IVcf7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2498c6bdcfa654a6f660c10cf6ae4c47","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2837852/Pillar_Biosciences_Dan_Harma.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This expanded collaboration aims to deliver rapid, cost-effective, and clinically actionable genomic insights through liquid biopsy testing. By increasing the local availability of plasma-based tumor profiling at leading clinical laboratories in China, the partnership seeks to accelerate diagnostic turnaround times and improve access to precision oncology solutions.","length":368,"tagName":"p"},{"type":"text","content":"China faces one of the world's highest cancer burdens, accounting for approximately 24% of new global cancer cases and 30% of cancer-related deaths, according to the World Health Organization's GLOBOCAN 2022 report. Lung, colorectal, and liver cancers remain among the most prevalent, and access to early detection and molecular diagnostics continues to be a signifi...